Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.
Publication
, Conference
Duvic, M; Kim, YH; Kuzel, TM; Pacheco, TR; Foss, FM; Parker, S; Frankel, SR; Chen, C; Ricker, JL; Arduino, JM; Randolph, S; Richon, VM; Olsen, EA
Published in: BLOOD
November 16, 2006
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2006
Volume
108
Issue
11
Start / End Page
122A / 122A
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., … Olsen, E. A. (2006). Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. In BLOOD (Vol. 108, pp. 122A-122A). Orlando, FL: AMER SOC HEMATOLOGY.
Duvic, Madeleine, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker, Stanley R. Frankel, et al. “Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.” In BLOOD, 108:122A-122A. AMER SOC HEMATOLOGY, 2006.
Duvic M, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. In: BLOOD. AMER SOC HEMATOLOGY; 2006. p. 122A-122A.
Duvic, Madeleine, et al. “Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.” BLOOD, vol. 108, no. 11, AMER SOC HEMATOLOGY, 2006, pp. 122A-122A.
Duvic M, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Randolph S, Richon VM, Olsen EA. Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. BLOOD. AMER SOC HEMATOLOGY; 2006. p. 122A-122A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2006
Volume
108
Issue
11
Start / End Page
122A / 122A
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology